Long-term treatment with low-dose, but not high-dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction

Journal of the American College of Cardiology

Volumn 42, Issue 3, 2003, Pages 541-548

  Igawa, Akihiko ^a   Nozawa, Takashi ^a   Fujii, Nozomu ^a   Kato, Bun Ichi ^a   Asanoi, Hidetsugu ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; GUANETHIDINE; NORADRENALIN;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; INHIBITION KINETICS; LONG TERM CARE; LOW DRUG DOSE; MALE; MORTALITY; MUSCLE LEVEL; NONHUMAN; NORADRENALIN BLOOD LEVEL; OSMOTIC MINIPUMP; OSMOTIC PUMP; OUTCOMES RESEARCH; PRIORITY JOURNAL; RAT; SURVIVAL; SURVIVAL TIME; SYMPATHETIC TONE; TREATMENT OUTCOME;

EID: 0041488816     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00650-8     Document Type: Article

References (36)

1. Schrier RW, Abraham WT. Mechanisms of disease: hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
2. Vatner DE, Vatner SF, Nejima J, et al. Chronic norepinephrine elicites desensitization by uncoupling the beta-receptor. J Clin Invest 1989;84:1741-8.
3. Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803-15.
4. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
5. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998;98:1329-34.
6. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325:618-24.
7. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
8. Manolis AJ, Olympios C, Sifaki M, et al. Suppressing sympathetic activation in congestive heart failure: a new therapeutic strategy. Hypertension 1995;26:719-24.
9. Azevedo ER, Newton GE, Parker JD. Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. J Am Coll Cardiol 1999;33:186-91.
10. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992;20 Suppl:1-10.
11. Dickstein K, Manhenke C, Aarsland T, Køpp U, McNay J, Wiltse C. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:1638-44.
12. Swedberg K, Bergh CH, Dickstein K, McNay J, Steinberg M. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure. J Am Coll Cardiol 2000;35:398-404.
13. Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002;105:1789-803.
14. Jones CG, Cleland JGF. Meeting report - the LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Failure 1999;1:425-31.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
16. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-7.
17. Igawa A, Nozawa T, Yoshida N, et al. Heterogeneous cardiac sympathetic innervation in heart failure after myocardial infarction of rats. Am J Physiol 2000;278:H1134-41.
18. Chien YW, Barbee RW, MacPhee AA, Frohlich ED, Trippodo NC. Increased ANF secretion after volume expansion is preserved in rats with heart failure. Am J Physiol 1988;254:R185-91.
19. Nozawa T, Igawa A, Yoshida N, et al. Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. Circulation 1998;97:2359-67.
20. Woosley RL, Nies AS. Guanethidine. N Engl J Med 1976;295:1053-7.
21. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996;93:1667-76.
22. Delehanty JM, Himura Y, Elam H, Hood WB Jr., Liang CS. Beta-adrenoceptor downregulation in pacing-induced heart failure is associated with increased interstitial NE content. Am J Physiol 1994;266:H930-5.
23. Zierhut W, Zimmer HG. Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989;65:1417-25.
24. Shen YT, Eng W, Bolduc D, Lynch JJ. Inhibition of sympathetic nerve activity partially preserves LV contractile function early in development of heart failure in conscious pigs. Circulation 1998;98 Suppl I:I159.
25. Van Kerckhoven R, Van Veen TAB, Boomsma F, Saxena PR, Schoemaker RG. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol 2000;397:113-20.
26. Nozawa T, Igawa A, Fujii N, et al. Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats. Heart Vessels 2002;16:51-6.
27. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
28. Sabbah HN, Stanley WC, Sharov VG, et al. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 2000;102:1990-5.
29. Corr PB, Gillis RA. Autonomic neural influences on the dysrhythmias resulting from myocardial infarction. Circ Res 1978;43:1-9.
30. Inoue H, Zipes DP. Results of sympathetic denervation in canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987;75:877-87.
31. Boura ALA, Green AF. Adrenergic neurone blocking agents. Ann Rev Pharmacol 1965;5:183-212.
32. Freis ED. Guanethidine. Prog Cardiovasc Dis 1965;8:183-93.
33. Oates JA. Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 9th edition. New York, NY: McGraw-Hill, 1996:780-808.
34. Evans B, Iwayama T, Burnstock G. Long-lasting supersensitivity of the rat vas deferens to norepinephrine after chronic guanethidine administration. J Pharmacol Exp Ther 1972;185:60-9.
35. Glaubiger G, Tsai BS, Lefkowitz RJ, Weiss B, Johnson EM Jr. Chronic guanethidine treatment increases cardiac beta-adrenergic receptors. Nature 1978;273:240-2.
36. Karlsberg RP, Penkoske PA, Cryer PE, Corr PB, Roberts R. Rapid activation of the sympathetic nervous system following coronary artery occlusion: relationship to infarct size, site, and haemodynamic impact. Cardiovasc Res 1979;13:523-31.